Abstract

<h3>Objective:</h3> To investigate whether osteoarthritis (OA) impacts stroke thrombectomy treatment rates or post-thrombectomy outcomes. <h3>Background:</h3> Osteoarthritis (OA) is a common condition affecting as many as 30 million Americans. While OA is not a direct risk factor for acute ischemic stroke, it can be associated with pre-stroke disability and influence patient selection for endovascular thrombectomy (EVT). Whether OA impacts post-EVT outcomes is currently unknown. <h3>Design/Methods:</h3> This was a retrospective study of the 2016–2019 National Inpatient Sample database. Adult patients with large vessel acute ischemic stroke were included. Patients with osteoarthritis were identified. Primary outcome was rate of EVT treatment in OA patients versus non-OA patients. Secondary outcomes include rates of discharge to home and in-hospital mortality after EVT treatment. Propensity score-matching (PSM) and multivariable logistic regression models were used to account for possible confounders. <h3>Results:</h3> 252,505 large vessel ischemic stroke patients were identified, of whom 21,500 patients (8.5% of study population) were diagnosed with OA. After PSM for 27 clinical variables, OA patients were 21.3% less likely to receive EVT than non-OA patients (14.4% vs. 18.3%, respectively; p&lt;0.001). In multivariable logistic regression analysis, OA was associated with 31% lower odds of receiving EVT (OR 0.69 [95%CI 0.63 to 0.76], p&lt;0.001), an effect size second only to dementia and larger than that of any other comorbidity captured in this study. Among patients who received EVT, multivariable logistic regression models showed that OA was not associated with different odds of being discharged home (OR 1.01 [95%CI 0.83 to 1.23], p=0.92); however, OA was associated with lower odds of in-hospital mortality compared to non-OA patients (OR 0.74 [95%CI 0.55 to 0.99], p=0.044). <h3>Conclusions:</h3> Large vessel ischemic stroke patients with OA were significantly less likely to receive EVT therapy despite similar post-EVT outcomes. These results warrant further investigation and prompt a critical review of current patient selection practices for EVT. <b>Disclosure:</b> Mr. Chen has received research support from National Institues of Health. Mr. Khunte has nothing to disclose. Dr. Colasurdo has nothing to disclose. Gaurav Jindal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Penumbra. Ajay Malhotra, 9122 has nothing to disclose. Dheeraj Gandhi has nothing to disclose. Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Calgary. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Ramar &amp; Paradiso. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Cole, Scott, Kissane. The institution of Dr. Chaturvedi has received research support from NINDS.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call